Johns Hopkins ABX Guide
Artemether/Lemefantrine
Artemether/Lemefantrine is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Treatment of acute, uncomplicated malaria infections due to Plasmodium falciparum in patients with ≥ 5 kg.
- Manufacturer does not recommend use for the treatment of severe malaria or the prevention of P. falciparum malaria.
- Most recent CDC guidelines recommend artemether/lumefantrine use for the treatment of severe malaria following administration of IV artesunate or while waiting for IV artesunate to arrive from CDC (see CDC website)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Treatment of severe malaria due to P. falciparum following administration of IV artesunate or while awaiting for IV artesunate to arrive from CDC.
- Treatment of uncomplicated P. vivax malaria (2015 WHO recommendations)[2].
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- Treatment of acute, uncomplicated malaria infections due to Plasmodium falciparum in patients with ≥ 5 kg.
- Manufacturer does not recommend use for the treatment of severe malaria or the prevention of P. falciparum malaria.
- Most recent CDC guidelines recommend artemether/lumefantrine use for the treatment of severe malaria following administration of IV artesunate or while waiting for IV artesunate to arrive from CDC (see CDC website)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Treatment of severe malaria due to P. falciparum following administration of IV artesunate or while awaiting for IV artesunate to arrive from CDC.
- Treatment of uncomplicated P. vivax malaria (2015 WHO recommendations)[2].
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: June 6, 2019
Citation
Avdic, Edina. "Artemether/Lemefantrine." Johns Hopkins ABX Guide, The Johns Hopkins University, 2019. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540604/all/Artemether_Lemefantrine.
Avdic E. Artemether/Lemefantrine. Johns Hopkins ABX Guide. The Johns Hopkins University; 2019. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540604/all/Artemether_Lemefantrine. Accessed September 28, 2022.
Avdic, E. (2019). Artemether/Lemefantrine. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540604/all/Artemether_Lemefantrine
Avdic E. Artemether/Lemefantrine [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2019. [cited 2022 September 28]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540604/all/Artemether_Lemefantrine.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Artemether/Lemefantrine
ID - 540604
A1 - Avdic,Edina,Pharm.D.
Y1 - 2019/06/06/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540604/all/Artemether_Lemefantrine
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
